HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Pyridinolcarbamate (P23)

Subscribe to New Research on Pyridinolcarbamate

A drug that has been given by mouth in the treatment of atherosclerosis and other vascular disorders, hyperlipidemias, and thrombo-embolic disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1408)

Also Known As:

P23; P 23; P-23; Pyricarbate; 2,6-Pyridinedimethanol-bis-(N-methylcarbamate); Anginin; Angioxine; Colesterinex; Duaxol; Duvaline; Gasparol; Lisator; Movecil; Parmidine; Prodectin; Sospitan; 2,6-Pyridinedimethanol, bis(methylcarbamate) (ester)

Networked: 709 relevant articles (9 outcomes, 35 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 58
- Carboxylic Acids: 83
  - Acyclic Acids
    - Carbamates: 172
      - Phenylcarbamates: 6
        Pyridinolcarbamate: 709
        N-nitrosopyridinol carbamate

Experts

1.	Lim, Megan S: 8 articles (06/2013 - 02/2004)
2.	Medeiros, L Jeffrey: 7 articles (11/2014 - 05/2002)
3.	Morris, Stephan W: 6 articles (01/2015 - 04/2002)
4.	Rassidakis, George Z: 5 articles (11/2014 - 06/2003)
5.	Elenitoba-Johnson, Kojo S J: 5 articles (03/2008 - 02/2004)
6.	Morris, S W: 5 articles (11/2001 - 03/2000)
7.	Heim, Sverre: 4 articles (11/2015 - 07/2005)
8.	Peña, Leandro: 4 articles (05/2015 - 12/2011)
9.	Flores, Ricardo: 4 articles (05/2015 - 12/2011)
10.	Fagoaga, Carmen: 4 articles (05/2015 - 12/2011)

Related Diseases

1.	Neoplasms (Cancer) 12/01/2013 - "R0 for recurrence (P = .005) and a disease-free interval >6 months (P < .001) were associated with survival after operation, whereas original tumor size (P = .47), grade (P = .8), and stage (P = .23) were not. " 07/01/2006 - "In this study, we investigated how p23 regulates ER target gene activation and affects tumor growth and progression. " 08/01/2002 - "The gene LZTS1 has been mapped to the 8p22 through p23 region and identified as a potential tumor suppressor based on loss of heterozygosity studies using primary esophageal tumors. " 10/01/2015 - "Tumor 1 had an unbalanced t(2;14)(p23;q22) translocation which led to the fusion gene KTN1-ALK. " 04/01/2015 - "Age, BMI, and the tumor diameter were not statistically different between the surgical and radiation group: 44 and 49 (± 11) years (p = .23), 24.6 (± 6.2) and 26.7 (± 5) (p = 0.33), and 22 (± 13) and 31 (± 11) mm (p = .09), respectively. "
2.	Hypertension (High Blood Pressure) 07/01/2015 - "Remission rates of hypertension and dyslipidemia were similar for T1D and T2D (66.7% versus 62.5%, P = .63 and 88.9% versus 75%, P = .23). " 11/01/2012 - "Among women, the meta-analysis indicated protective effects at <10 g/d (RR, 0.87; 95% CI, 0.82-0.92; P<.001) and a trend toward decreased risk of hypertension with alcohol consumption 11 to 20 g/d (RR, 0.9; 95% CI, 0.87-1.04; P=.17), whereas a significantly increased risk of hypertension was indicated with heavy alcohol consumption of 21 to 30 g/d (RR, 1.16; 95% CI, 0.91-1.46; P=.23) and 31 to 40 g/d (RR, 1.19; 95% CI, 1.07-1.32; P=.002). " 01/01/1984 - "It is recommended that TICC associated with arterial hypertension be treated by sodium salicylate, whereas in TICC associated with atherosclerosis the administration of antikinin drugs is indicated (parmidin, prodectin)." 03/14/2005 - "Cyclooxygenase-2 inhibitors were associated with a nonsignificantly higher RR of causing hypertension compared with placebo (RR, 1.61; 95% confidence interval [CI], 0.91-2.84; P = .10) and nonselective NSAIDs (RR, 1.25; 95% CI, 0.87-1.78; P = .23). "
3.	Hemorrhage 10/01/1965 - "Trial use of an antibradykinin agent, B 23 (Anginin), for the prevention of hemorrhage]." 10/01/2014 - "MWa patients tended to more frequently rebleed and more frequently require endoscopic therapy (both parameters: 4/17 vs. 8/73, p = .23) and tended to more frequently require surgery or angiography to control bleeding (3/17 vs. 3/73, p = .08). " 03/01/2012 - "The proportion of injections with bleeding [10.8% (5 mm/20 U) vs 5.83% (8 mm/20 U), P = .23, and 4.92% (5 mm/60 U) vs 6.56% (8 mm/60 U), P = .73] and the proportion of patients with bruising [8.11% (5 mm/20 U) vs 10.81% (8 mm/20 U), p = .56, and 21.05% (5 mm/60 U) vs 26.32% (8 mm/60 U), p = .65] at injection sites were similar. " 05/01/2013 - "Major stroke, life-threatening bleeding, all-cause 30-day mortality (HD 15.2%, severe CKD 8.3%, moderate CKD 8.3%, mild CKD 6.7%, normal 1.8%, P = .007) and 1-year survival (HD 54.8%, severe CKD 67.2%, moderate CKD 80.0%, mild CKD 85.2%, normal eGFR 91.4%, HD vs severe CKD P = .23, severe CKD vs moderate CKD P = .002, moderate CKD vs mild CKD P = .04, moderate CKD vs normal eGFR P = .03, by log-rank test) differed significantly across groups. " 08/01/1995 - "The control of active bleeding was 12/15 (80%) in the sclerotherapy group and 18/19 (94%) in the ligation group (P = .23). "
4.	Arteriosclerosis 07/01/1978 - "Anginin seems to be a good drug for patients with moderately advanced combined peripheral and central arteriosclerosis." 04/01/1975 - "[The importance of pyridinolcarbamate and clofibrate association in the treatment of arteriosclerosis]." 01/01/1975 - "[The importance of pyridinolcarbamate and clofibrate association in the treatment of arteriosclerosis]." 07/01/1978 - "[Therapeutic efficacy of pyridinolcarbamate (Anginin) in patients with combined cerebral and peripheral arteriosclerosis]." 01/01/1989 - "The patient received since four years pyridinolcarbamate (Prodectin) because of obliterating peripheral arteriosclerosis. "
5.	Dyslipidemias (Dyslipidemia) 07/01/2015 - "Remission rates of hypertension and dyslipidemia were similar for T1D and T2D (66.7% versus 62.5%, P = .63 and 88.9% versus 75%, P = .23). "

Related Drugs and Biologics

1.	Pyridinolcarbamate (P23)
2.	Luciferases
3.	Dihydrotachysterol (AT 10)
4.	Antral
5.	cholesteryl-6-pyrenylhexanoate (ChPH)
6.	Antigens
7.	Proteins (Proteins, Gene)
8.	DNA (Deoxyribonucleic Acid)
9.	RNA (Ribonucleic Acid)
10.	Transcription Factors (Transcription Factor)

Related Therapies and Procedures

1.	Heterologous Transplantation (Xenotransplantation)
2.	Sclerotherapy
3.	Ligation
4.	Endometrial Ablation Techniques
5.	Transplants (Transplant)